• भारत सरकार के विज्ञान एवम प्रौदयोगिकी मंत्रालय के जैव प्रौदयोगिकी विभाग की स्वायत्त संस्थान
  • Home
  • Faculty Profile
  1. Hingankar, K., Deshpande, S., Das, P., Rizvi, Z.A., Wibmer, C.K., Mashilo, P., Burns, A., Barman, S., Zhao, F., Ansari, M.Y., Mukherjee, S., Torres, J. T., Chattopadhyay, S., Mehdi, F., Sutar, J., Rathore, D.K., Pargai, K., Singh, J., Sonar, S., Jakhar, K., Bhattacharyya, S., Mani, S., samal, S.., Singh, S., Dandotiya, J., Kshetrapal, P., Thiruvengadam, R., Batra, G., Medigeshi, G.R, Ward, A., Bhatnagar, S.,  Awasthi, A., Sok, D.*, Bhattacharya, J.*. (2022). Potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against SARS-CoV-2 Delta. PLOS Pathogens Apr 28;18(4):e1010465
  2. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Srivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Kumar, P., Taneja, J., Akshay and Vohra, Tarini and Zaheer, Aymaan and Rathore, Deepak, Khan, Naseem Ahmed, Shaman, Heena, Ahmed, Shubbir, Kumar, Rajesh,  Deshpande, Suprit, Subramani, Chandru, Wadhwa, Nitya, Gupta, Nimesh, Pandey, Anil K., Bhattacharya, Jayanta, Agrawal, Anurag, Vrati, Sudhanshu, Bhatnagar, Shinjini, Garg, Pramod Kumar and COVID-19 Research, DBT Consortium (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative case-control study and a Mechanistic Study of Post-Vaccination Immune Responses. Lancet Infect Dis. (Apr;22(4):473-482.
  3. Mullick, R., Sutar, J., Hingankar, N., Deshpande, S., Thakar, M., Sahay, S., Ringe, R.P., Mukhopadhyay, S., Patil, A., Bichare, S., Murugavel, K.G., Srikrishnan, A.K., Goyal, R., Sok, D. Bhattacharya, J.* (2021). Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities. Retrovirology 18: 12
  4. Sutar, J; Deshpande, S; Mullick, R, Hingankar, N., Patel, V., Bhattacharya, J*. (2021). Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivityPLOS ONE.16(5): e0251969.
  5. Kumar, R., Deshpande, S., Sewall, L.M., Ozorowski, G., Cottrell, C.A., Lee, W., Holden, L.G., Richey, S.T., Chandrawacar, A.S., Dhiman, K., Ashish, Kumar, V., Ahmed, S., Hingankar, N., Kumar, N., Murugavel, K.G., Srikrishnan, A.K., Sok, D., Ward, A.B.,Bhattacharya, J.* (2021). Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer. PLOS Pathogens17 (4): e1008977.
  6. Sutar, J., Padwal., V., Sonawani, A., Nagar, V., Patil, P, Kulkarni, B., Hingankar, N., Deshpande, S., Idicula-Thomas, S., Jagtap, J., Bhattacharya, J., Bandivdekar, A., Patel, V. (2019). Effect of diversity in gp41 membrane proximal external region of primary HIV-1 Indian subtype C sequences on interaction with broadly neutralizing antibodies 4E10 and 10E8. Virus Res. 273: 197763.
  7. Pergu, R., Dagar, S., Kumar, H., Kumar, R., Bhattacharya, J., and Mylavarapu, SVS (2019). The chaperone ERp29 is required for tunneling nanotube formation by stabilizing MSec. J Biol. Chem. May 3;294(18):7177-7193.
  8. Bhattacharya, J.(2019). HIV prevention & treatment strategies - Current challenges & future prospects (EDITORIAL). Indian J Med Res. 148, December 2018, pp: 671-674
  9. Kumar, R., Qureshi, H., Deshpande, S., Bhattacharya, J* (2018). Broadly neutralizing antibodies in HIV-1 treatment and prevention. Therapeutic Advances in Vaccines and Immunotherapy 6 (4): 61-68.
  10. Das, S.*, Bansal, M., Bhattacharya, J. (2018). Characterization of the membrane-bound form of the chimeric, B/C recombinant HIV-1 Env, LT5.J4b12C. J Gen. Virol 99 (10): 1438-1443
  11. Paneerselvam, N., Bhattacharya, J., Srikrishnan, A.K., Goyal, R., Ravichandran, S.C., Patil, S., Saravanan, S., Deshpande, S., Ramachandran, V., Solomon, S.S., Singla, N., Mukherjee, J., Murugavel, K.G. (2018). Broad Neutralization Response in a Subset of HIV-1 Subtype C infected Viremic Non-Progressors from Southern India. J Gen. Virol. 99: 379-393
  12. Kumar, R., Ozorowski, G., Kumar, V., Holden, L., Shrivastava, T., Patil, S., Deshpande, S., Ward, A.B., Bhattacharya, J*. (2017). Characterization of a stable HIV-1 B/C recombinant, soluble and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. Journal of Biological Chemistry. 292 (38): 15849-15858
  13. Qureshi, H. and Bhattacharya, J.* (2017). Dual immunity concomitantly suppresses HIV-1 progression. Trends in Microbiol. 25 (5): 334-335.
  14. Khan, L., Kumar, R., Thiruvengadam, R., Parray, H.A., Makhdoomi, M.A., Kumar, S., Aggarwal, H., Mohata, M., Hussain, A.W., Das, R., Varadarajan, R., Bhattacharya, J., Vajpayee, M., Murugavel, K.G., Solomon, S., Sinha, S., Luthra, K.* (2017). Cross-neutralizing anti-HIV-1 human single chain variable fragments (scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library. Scientific Reports. Mar 23; 7: 45163.
  15. Deshpande, S., Patil, S., Kumar, R., Shrivastava, T., Srikrishnan, A.K., Murugavel, K.G., Koff, W.C., Chakrabarti, B.K., Bhattacharya, J*. (2016). Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies. Retrovirology 13: 41
  16. Despande, S., Patil, S., Kumar, R., Hermanus, T., Murugavel, K.G., Solomon, S., Morris, L., Bhattacharya, J*.(2016)HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology30;13(1):60
  17. Patil, S., Kumar, R., Deshpande, S., Samal, S., Shrivastava, T., Boliar, S., Bansal, M., Chaudhary, N.K., Srikrishnan, A.K., Murugavel, K.G., Solomon, S., Simek, M., Koff, W.C., Goyal, R., Chakrabarti, B.K., Bhattacharya, J.*(2016). Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C Infected Elite Neutralizer Mediate Autologous Virus Escape through Novel Mutations in V1 Loop. Journal of Virology 90 (7):3446-3457.
  18. Khan, L., Makhdoomi, M.A., Kumar S., Nair, A., Andrabi, R., Clark, B.E., Auyeung, K., Bhattacharya, J., Vajpayee, M., Wig, N., Pantophlet, R., Luthra, K. (2015). Identification of CD4-binding site dependent plasma neutralizing antibodies in an HIV-1 infected Indian individual PLoS One 10(5):e0125575
  19. Boliar S, Das, S., Bansal, M., Shukla, B.N., Patil, S., Shrivastava, T., Samal, S., Goswami, S., King, C.R., Bhattacharya, J., Bimal K Chakrabarti (2015). An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies. PLoS One 10(3): e0122443
  20. SV Kulkarni, M Bala, J Bhattacharya, A Risbud. (2015). Detection of mutations in mtrR gene in quinolone resistant strains of N.gonorrhoeae isolated from India. Indian Journal of Medical Microbiology, 33(2): 277-281
  21. Patil, S., Choudhary, I., Chaudhary, N., Ringe, R, Bansal, M, Shukla, B.N., Boliar, S., Chakrabarti, B.K., and Bhattacharya, J.* (2014). Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in context dependent manner. Virology 462-463: 266–272
  22. Tilghman MW, Bhattacharya J., Deshpande S, Ghate M, Espitia S, Grant I, Marcotte TD, Smith D, Mehendale S. (2014). Genetic attributes of blood-derived subtype-C HIV-1 tat and env in India and neurocognitive function. J Med Virol. 86(1): 88-96
  23. Mahajan S.D, Gaekwad A, Pawar J, Tripathy S, Ghate M, Bhattacharya J, Singh HO, Schwartz SA, Paranjape R, Gangakhedkar R. (2014). Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism. Curr HIV Res. 13: 98-108
  24. Ringe, R. and Bhattacharya, J.* (2013). Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1. Therapeutic Adv in Vaccines. 1: 67-80
  25. Gautam, A. and Bhattacharya, J.*(2013). Evidence that Vpu Modulates HIV-1 Gag-Envelope Interaction towards Envelope Incorporation and Infectivity in a Cell Type Dependent Manner. PLoS One 8(4): e61388
  26. Ghate M, Tripathy S, Gangakhedkar R, Thakar M, Bhattacharya J, Choudhury I, Risbud A, Bembalkar S, Kadam D, Rewari BB, Paranjape R. (2013). Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report. Indian J Medical Research 137(5):942-9
  27. Choudhary, I., Chimanpure, V., Patil, A., and Bhattacharya, J.* (2013).Single step detection of HIV-1 proviral DNA and housekeeping β-actin gene from dried blood spots by monoplex polymerase chain reaction. J Virol Methods 187: 203-206.
  28. Kulkarni S, Bala M, Sane S, Pandey S, Bhattacharya J, Risbud A. (2012). Mutations in the gyrA and parC genes of quinolone-resistant Neisseria gonorrhoeae isolates in India. Int J Antimicrob Agents. 40(6):549-53
  29. Patil, A. and Bhattacharya, J.* (2012). Natural deletion of L35Y36 in p6 gag eliminate LYPXnL/ALIX auxiliary virus release pathway in HIV-1 subtype C. Virus Research 170: 154-158
  30. Gautam, A.*, Patil, A. and Bhattacharya, J. (2012). Gag-Vpu cross talk modulating HIV-1 envelope incorporation and infectivity in cell-type dependent manner. BMC Infectious Diseases 12 (Suppl 1): P49     
  31. Ringe, R., Das, L., Choudhury, I., Sharma, D., Paranjape, R., Chauhan, V.S., and Bhattacharya, J.* (2012). Unique sequence pattern in the C2V3 region in HIV-1 envelope obtained from broadly neutralizing plasma of an antiretroviral naïve chronically infected patient conferred enhanced neutralization by exposition of discontinuous neutralizing epitopes. PLoS One7(10):e46713.
  32. Ringe, R., and Bhattacharya, J.* (2012).Association of enhanced HIV-1 neutralization by a single residue substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity. PLoS One 7(5): e37157
  33. Ringe, R., Phogat, S. and Bhattacharya, J*. (2012). Subtle alteration of residues including N-linked glycans in V2 loop modulates HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. Virology 426: 34–41
  34. Gharu, L., Ringe, R., and Bhattacharya, J.* (2012). Evidence of extended alternate coreceptor usage by HIV-1 clade C envelope obtained from an Indian patient. Virus Research 163 (2012) 410–414
  35. Ringe, R., Sharma, D., Zolla-Pazner, S., Phogat, S., Risbud, A., Thakar, M., Paranjape, R and Bhattacharya, J.* (2011)A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop, Virology 418: 123–132
  36. Gharu, L., Ringe, R., and Bhattacharya, J*. (2011). HIV-1 clade C envelopes obtained from late stage symptomatic Indian patients varied in their ability towards relative CD4 usages and sensitivity to CCR5 antagonist TAK-779. Virus Research 158: 216–224
  37. Mukhopadhyay, S., Ringe, R., Patil, A., Paranjape, R and Bhattacharya, J*. (2011) Characterization of circulating HIV-1 env genes in plasma of two antiretroviral naïve slow progressing patients with broad neutralizing antibody response with evidence of recombination. AIDS Res Human Retroviruses28(7):739-45.
  38. Jadhav, S., Tripathy, S., Kulkarni, S., Chaturbhuj, D., Ghare, R., Bhattacharya, J.* and Paranjape, R. (2011) Genetic conservation in gp36 transmembrane sequences of Indian HIV-2 isolates. AIDS Res Human Retroviruses(May 19. [Epub ahead of print] PMID: 21453135)
  39. Gharu, L., Ringe, R., Anupindi S., Patil, A and Bhattacharya, J.* (2011). Evidence of HIV-1 clade C env clones containing low V3 loop charge obtained from an AIDS patient in India that uses CXCR6 and CCR8 for entry in addition to CCR5. AIDS Res Human Retroviruses 27 (2): 211-219
  40.  Ringe, R., Thakar, M. and Bhattacharya, J.* (2010). Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade 1 C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection. Retrovirology 7:76
  41. Sharma, D. and Bhattacharya, J.* (2010) Evolutionary constraints acting on DDX3X protein potentially interferes with Rev-mediated nuclear export of HIV-1 RNA. PLoS One5(3): e9613.
  42. Patil, A., Gautam, A and Bhattacharya, J.* (2010) Evidence that Gag facilitates HIV-1 envelope association both in GPI-enriched plasma membrane and detergent resistant membranes and facilitates envelope incorporation onto virions in primary CD4+ T cells. Virology J7: 3
  43. Sharma, D. and Bhattacharya, J.* (2009). Dynamics of evolution of HIV-1 Rev binding host factors with their predicted role in HIV associated neuropathogenesis. Journal of Neurovirology, 15 (Supplementary 1): 88-89 (DOI: 10.1080/13550280903016074)
  44. Gharu, L., Ringe, R., Pandey, S., Paranjape, S., and Bhattacharya, J.* (2009). HIV-1 clade C env clones obtained from an Indian patient exhibiting expanded coreceptor tropism are presented with naturally occurring unusual amino acid substitutions in V3 loop. Virus Research 144:306-314.
  45.  Sharma, D and Bhattacharya, J.* (2009). Cellular and Molecular Basis of HIV-Associated Neuropathogenesis. Indian Journal of Medical Research 129: 637-651
  46. Ringe, R., Gharu, R., Satyakumar, A., Pandey, S., Thakar, M. and Bhattacharya, J *. (2008). Genetic and Neutralization Properties of HIV-1 India Clade C Envelope in Recent Infection: Correlation with CCR5 Usage and Clonal Divergence. AIDS Res Human Retrovirus 24 Supplement 1: 33-33. (DOI: 10.1089/aid.2008.9997a).
  47. The Six Week Extended Dose Nevirapine (SWEN) Study Team (2008). Extended Dose of Nevirapine to Six Weeks of Age for Infants in Ethiopia, India and Uganda: A Randomized Trial for Prevention of HIV Transmission through Breastfeeding. Lancet 372: 300-313
  48. Lakhashe, S., Tripathy, S.P., Paranjape, R.S. and Bhattacharya, J.* (2008). Evidence of a Novel B/C Recombinant Exhibiting Unique Breakpoints of Nearly Full Length HIV-1 Genome in North Eastern India. AIDS Res Human Retroviruses 24 (2): 229-234
  49. Lakhashe, S., Tripathy, S.P., Paranjape, R.S. and Bhattacharya, J.* (2008). Characterization of B/C Recombinants of Nearly Full Length HIV-1 in North Eastern India with Mosaics Identical to ARE195FL but with a Different Ancestral Origin. AIDS Res Human Retroviruses 24 (1): 92-99
  50. Peters P.J., Sullivan, W.M, Duenas Decamp, M., Bhattacharya, J., Ankghuambom, C., Brown, R., Luzuriaga, K., Bell, J., Simmonds, P., Ball, J and Clapham, P.R. (2006). Macrophage-tropic R5 envelopes are infrequent in blood, lymph nodes and semen: Implications for transmission and pathogenesis. Journal of Virology 80: 6324-6332
  51. Bhattacharya, J., Repik, A. and Clapham, P.R. (2006). Gag regulates Human Immunodeficiency virus type 1 envelope association with detergent resistant membranes. Journal of Virology 80: 5292-5300
  52. Bhattacharya, J., Peters, P.J., and Clapham, P.R. (2004). Human Immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: Impact on association with membrane lipid rafts and incorporation onto budding virus particles. Journal of Virology, 8: 5500-5506.
  53. Bhattacharya, J.,* Peters, P.J.,* Hibbitts, S.,* Dittmar, M.T., Simmons, G.S, Bell, J., Simmonds, P.S. and Clapham, P.R. (2004). Biological analysis of HIV-R5 envelopes amplified from brain and lymph node tissue of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in brain that confer an enhanced tropism and fusigenicity for macrophages. Journal of Virology 78: 6915-6926 [* equal contribution].
  54. Bhattacharya, J., Peters, P. J., and Clapham, P.R. (2003). CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS: S35-S43.
  55. Bhattacharya, J., Samanta, S., Hoque, K.M., Mukherjee, A. and Chakrabarti, M.K. (2001). Escherichia coli heat stable enterotoxin receptors and guanylyl cyclase activity in the intestinal brush border membrane of hamsters and guinea pigs. Indian Journal of Medical Research, 113; 5-10
  56. Bhattacharya, J. and Chakrabarti, M.K. (1999). Binding of Escherichia coli heat stable toxin and rise of guanylyl cyclase activity in the brush border membranes of rabbit intestinal epithelial cells. Journal of Diarrhoeal Diseases Research; 1; 28-33.
  57. Basu, I., Mitra, R., Saha, P.K., Ghosh, A.N., Bhattacharya, J., Chakrabarti, M.K., Takeda, Y. and Nair G.B. (1999). Morphological and cytoskeletal changes caused by non-membrane damaging cytotoxin of Vibrio cholerae on INT 407 and HeLa cells. FEMS Microbiology Letters. 179(2): 255-63.
  58. Bhattacharya, J. and Chakrabarti, M.K. (1998). Rise of intracellular free calcium levels with activation of inositol triphosphate in a human colonic carcinoma cell line (COLO 205) by heat-stable enterotoxin of Escherichia coli. Biochimica et Biophysica Acta.1403 (1): 1-4.
  59. Chakrabarti, M.K., Bhattacharya, J., Bhattacharya, M.K., Nair, G.B., Bhattacharya, S.K., Mahalanabis. D. (1999). Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr. 88 (2): 161-5.
  60. Chaudhuri, A.G., Bhattacharya, J., Nair, G.B., Takeda, T. and Chakrabarti, M.K. (1998). Rise of cytosolic Ca2+ and activation of membrane-bound guanylyl cyclase activity in rat enterocytes by heat-stable enterotoxin of Vibrio cholerae non-01. FEMS Microbiology Letters. 1998 160(1): 125-9.
  61. Bhattacharya, J., Chaudhuri AG, Sinha AK, Samanta AK, Chakrabarti MK. (1997) Binding of Escherichia coli heat-stable enterotoxin and rise of cyclic GMP in COLO 205 human colonic carcinoma cells. FEMS Microbiology Letters; 156 (1): 79-83.
  62. Chakrabarti, M.K., Bhattacharya, M.K, Bhattacharya, J., Bhattacharya, S.K., and Mahalanabis, D. (1998). Evaluation of different antibiotics in inhibiting colonization of Vibrio cholerae O1 and O139 in the rabbit intestine. Chemotherapy. 44(2): 108-11.
  63. Chakrabarti, M.K. and Bhattacharya, J. (1996). Cyclic 3’ 5’ adenosine monophosphate in bacteria. Indian Journal of Physiology and Allied Science, 50: 128-135.
  64. Chakrabarti, M. K., Bhattacharya, J., Sinha, A.K., De, S.P. (1995). Role of outer membrane proteins on the adherence of Vibrio parahaemolyticus to rabbit intestinal epithelial cell in vitro. International Journal of Medical Microbiology. 282(4): 436-41.
  65. Chakrabarti, M.K., Bhattacharya, J. and De, S.P. (1995). Hemagglutinating activities of different strains of Vibrio parahaemolyticus. Medical Science Research 23: 497-498.

1.     Ambrose CS, Bhattacharya J, Fox CB, McIntosh ED, Stern PL. Therapeutic Advances in Vaccines. 2013 SAGE Publication, London, UK. May; 1(1):3-5. doi: 10.1177/2051013613486264.

2.     Bhattacharya, Jayanta. Unconventional technologies accelerating HIV Vaccine Discovery. Spinco Biotech CuttingEdge Newsletter. September 2015: page 22-24

  1. Provisional Patent Application Filed by THSTI & IAVI

Partners: THSTI, IAVI,

Name of the Invention: Potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant

Indian Patent Application No: 202111059095; Ref: IP0694

Filing date: December 17, 2021

Inventors: Jayanta Bhattacharya, Nitin Hingankar, Payel Das, Suprit Deshpande, Pallavi Kshetrapal, Ramachandran Thiruvengadam, Amit Awasthi, Zaigham Abbas Rizvi


  1. Provisional Patent Application Filed by THSTI & IAVI

Partners: THSTI, IAVI,


Indian Patent Application No: 202111038519; Ref: IP0636

Filing date: August 25, 2021

Inventors: Jayanta Bhattacharya, Nitin Hingankar, Payel Das, Suprit Deshpande, Pallavi Kshetrapal, Ramachandran Thiruvengadam, Amit Awasthi


  1. South Africa Patent granted

              Partners: THSTI, IAVI, YRGCARE

              Name of the Invention: Engineered HIV-1 envelope immunogen

               SOUTH AFRICAN PATENT grant NO: 2020/05470

              Grant date: 30 March 2022

Inventors: J. Bhattacharya (IAVI), R. Kumar (THSTI), S. Deshpande (THSTI), V. Kumar (THSTI), K.G Murugavel (YRGCARE)


  1. Provisional Patent Application Filed by THSTI


Application reference number: 201611004727


      Filing date:  February 10, 2016

Inventors: Jayanta Bhattacharya (IAVI), Suprit Deshpande (THSTI), Shilpa Patil (THSTI), Rajesh Kumar (THSTI), K.G. Murugavel (THSTI)


  1. Provisional Patent Application Filed by THSTI

Partners: THSTI, IAVI

Application reference No: 201711016548

Filing date: 

Name of the invention: Engineered Recombinant Protein Antigen of Trimeric Mimic of HIV-1 Envelope Glycoprotein Spike

Filing date: 2017

Inventors: Jayanta Bhattacharya (IAVI), Rajesh Kumar (THSTI), Vivek Kumar Yadav (THSTI), Shilpa Patil (THSTI)


  1. International Publication Reference No: WO 2017/007646 Al

Partners: THSTI, IAVI

International Publication Reference No: WO 2017/007646 Al

International Publication Date: 12 January 2017


Filing date: 29 June 2016

International application ref no: PCT/US2016/039936

Inventors: Jayanta Bhattacharya (IAVI), Suprit Deshpande (THSTI), Shilpa Patil (THSTI), Bimal K Chakrabarti (IAVI)


  1. International Publication Reference No: WO 2016/065252 A2

Partners: THSTI, IAVI

International Publication Reference No: WO 2016/065252 A2

International Publication Date: 28 April 2016


Filing date: 23 October 2015

International application ref no: PCT/US20 15/057098

Inventors: Bimal K Chakrabarti (IAVI), Saikat Boliar (THSTI), Supratik Das (THSTI), Tripti Srivastava (THSTI), Charles Richter King (IAVI), Jayanta Bhattacharya (IAVI), Sweety Samal (THSTI)

  • Indian Council of Medical Research: Evaluation of the magnitude, kinetics and longevity of humoral and cellular immune responses to SARS-CoV-2 variants in vaccinated and naturally infected individuals.

Role: Lead PI & Project Coordinator; AIIMS PIs: Prof Randeep Guleria & Prof Anant Mohan

Type: Multicentric Project (THSTI, AIIMS); Lead Institute: THSTI

Awarded Year: Approved & pending funding; Funding Period: 2022-2024

Funding Amount: INR 1.3 crores


  • Bill & Melinda Gates Foundation (BMGF): Global Immunology & Immune Sequencing for Epidemic Response (GIISER South Asia).

Role: Co-PI & Lead,Monoclonal Ab discovery & development component; Type: Multicentric Project (THSTI & IGIB)

Awarded Year: October 2021; Funding Period: 2021-2023

Funding Amount: US $1,335,437 (fort the Ab work)


  • USAID (United States Agency for International Development) through IAVI: Accelerating the Development of Vaccines and New Technologies to Combat the AIDS Epidemic (ADVANCE) through South-South Collaboration.

Role: Lead PI (India, THSTI)

Type: Multicentric Project (THSTI, YRGCARE & African partners at UVRI, KEMRI, UKZN, NICD, AHRI, HIL-Imperial College)

Awarded Year: January 2021; Funding Period: 2021-2025

Funding Amount: Up to $100,000 / year


  • Department of Biotechnology, (Development of therapeutic broadly neutralizing monoclonal antibodies against circulating HIV-1 clade C in children and adults")

Role: Lead PI and Project Coordinator; Type: Multicentric Project (THSTI, AIIMS, IISc, CSTM, IGICH, JNIMS, NIRT, NARI)

Awarded Year: Project Approved, (Formal Award Pending); Funding Period: 3 YEARS

Funding Amount: INR 799.93 lakhs


  • Wellcome Trust-DBT India Alliance Team Science Grant (TSG).Developing broadly neutralizing monoclonal antibody mediated prevention and treatment strategy by assessing their effectiveness in neutralizing HIV‐1 subtype C circulating in India across different regions and distinct risk groups.

Role: Lead PI

Partner Institutions: ICMR-NIRRH, Mumbai, YRGCARE, Chennai, Nair Hospital, Mumbai (West); Calcutta School of Tropical Medicine (East), YRGCARE CRC network (South, North-East, Central) Global Collaborators: Dr David Montefiori (Duke University, Durham, NC, USA) and IAVI Neutralizing Antibody Center, TSRI, La Jolla, California, USA

Awarded Year(2019). Funding period: 2020-2025;

Funding Amount: INR 9,21,17,530


  • Science & Engineering Research Board (SERB).Department of Science & Technology, Identification, characterization and optimization of monoclonal antibodies that broadly neutralize entry of HIV-1 subtype C predominantly circulating in India.

Role: PI;

Awarded Year(2019). Funding period: 2020-2023;

Funding Amount: INR 55,67,220/-


  • The Research Council of Norway. GLOBVAC (Global Health & Vaccination Research), (a tripartite collaboration between University of Oslo, Neutralizing Antibody Center, International AIDS Vaccine Initiative at The Scripps Research Institute, La Jolla, California, USA and Translational Health Science & Technology Institute, DBT, India), “Developing HIV broadly neutralizing antibodies as a prevention product for global access through antibody half-life extension engineering”.

Role: PI (THSTI site);

Awarded Year: 2019, Funding period: 2019-2022; Funded Amount: NOK 75,06,000 


  • Department of Biotechnology, Govt of India.  “Indo-European Consortium for Next Generation Influenza Vaccine Innovation” under Horizon 2020 program

Role: Co-investigator 

Awarded Year: 2019, Funding period: 2020-2025

Collaborating Institutions from 19 Partnering Countries (India [NII, THSTI, PHFI, IIT-M, KEM], Germany, Belgium, Norway, France, Spain, USA, Netherlands.


  • Department of Biotechnology & Department of Science & Technology (under Indo-South Africa joint proposal). Isolation and Characterization of Monoclonal Antibodies from HIV-1 Subtype C Infected Individuals.

Role: PI & Program Coordinator (India) (South Africa PI: Prof Lynn Morris):

AWARDED Year: December 2017. Total Awarded Amount: INR 2,04,64,636.


  • Department of Biotechnology. National Bioscience Award Project Status: Completed.

Role: PI. Period: 2014-2017 Awarded Amount: INR 15, 00,000 (3 Years).


  • Department of Biotechnology. “Construction and Characterization of Genetically Engineered Chimeric HIV-1 Envelope Protein Modulating Virus Neutralization: Implication and Relevance in Vaccine development”Status: Completed.

Role: PI. Awarded amount: INR 53.87 Lacs. Period: 2010-2013.


  • Department of Science and Technology. “Identification of neutralizing antibody epitopes on Indian and South African HIV-1 subtype C viruses for HIV vaccine design”.Status: Completed

Role: PI; Awardedamount: > INR 136 Lacs. Period: 2011-2014, Type: Multi-centric collaborative project between Indian institutes (NARI, AIIMS, ICGEB, YRGCARE) and South Africa (NICD, Johannesburg).


  • NIH Fogarty funded Vanderbilt NARI-NIE-Informatics Training Program (VNNIT) [1D43TW008440-01].

Role: Co-Principal Investigator (PI: Dr S M Mehendale).


  • Department of Biotechnology / Indian Council of Medical Research (DBT/ICMR)[2006-2010]. Neutralization Epitope Mapping in HIV-1 Envelope of Indian Origin and Construction of Envelope- Based Peptide Immunogen for Generation of Broadly Cross-Reactive Neutralizing Antibodies.

Role: Principal Investigator Status: Completed.

Awarded amount: INR 54 Lakhs.


  • Department of Biotechnology/Indian Council of Medical Research (DBT/ICMR)[2006-2010]. Comprehensive molecular analysis of HIV incidence, genetic diversity and anti-retroviral drug-resistance mutations in diverse risk groups across wide geographic locales of India.

Role: PI, Status: Completed

Awarded amount: INR 75 Lakhs.


  • Department of Biotechnology/Indian Council of Medical Research (DBT/ICMR)[2006-2010]. Establishment of virtual knowledge and resource center for reagents, protocols and technology in context with research in HIV and AIDS.

Role: PI & Project Coordinator (Co-PIs: Drs Shahid Jameel & Ramesh Paranjape) Status: Completed

Awarded amount: INR 9.92 Lakhs.


  • Collaboration of Vaccine Development-Vaccine Immune Monitoring Consortium (CAVD/VIMC): Funded by Bill and Melinda Gates Foundation:

Role: Co-investigator, India site (PI: David Montefiori, Duke University) Status:Completed.


  • American Foundation of AIDS Research (amfAR), New York, USA [2004-2006].

Role: Principal Investigator Status: Completed;

Awarded amount: US$ 99,000.

  1. Member, National Selection Committee, United States-India E­­ducational Foundation (USIEF) – the Fulbright Commission in India, New Delhi (2019).
  2. Chief Guest & Faculty, Manipal College of Pharmaceutical Sciences, Kasturba Medical College, Manipal Academy of Higher Education, Manipal University (Dept of Health Research & ICMR sponsored National Level Workshop on Clinical and Translational Research for Precision Medicine, 5-6th December, 2019).
  3. Member, Review Board, NIHR Global Health Policy and Systems Research, UK (https://www.nihr.ac.uk/).
  4. Reviewer (2019), Scheme for Transformational and Advanced Research in Sciences (STARS), Ministry of Human Resource Development (MHRD), Department of Higher Education Science Bureau, Govt of India, being implemented by the Indian Institute of Science, Bengaluru, Karnataka 560012.
  5. Member, IAVI global key influencer group (2018-onward)
  6. Chairperson, THSTI Purchase Sub-Specification Committee
  7. Chairperson, Scientist Recruitment for ICMR Institution, 2019
  8. Member, Expert Committee, constituted by DBT to review proposal of CCBT, inSTEM, Bengaluru 19 February 2019.
  9. Special Invitee, DST-SERB Task Force Meeting, New Delhi (ICGEB); 21-22 December 2018.
  10. MVP Award from the International AIDS Vaccine Initiative, New York, USA, July 2018
  11. Recognition by IAVI as Key Influencer of the organization by the CEO, IAVI, Dr Mark Feinberg.
  12. MVP Award from the International AIDS Vaccine Initiative, New York, USA, October 2017
  13. Member, Joint Committee on S&T Cooperation (Indo-South Africa Bilateral Collaboration), Department of Science & Technology, Govt. of India in 2017.
  14. ‘On the Spot Award of Excellence’, by the International AIDS Vaccine Initiative, New York, USA, February, 2015
  15. Member, National Academy of Science (MNASc.), India (Allahabad), 2014.
  16. National Bioscience Award for Career Development, 2013, Ministry of Science and Technology, Govt. of India.
  17. Member, DBT Infectious Disease Biology Task Force (2012-2013)
  18. Member, Advisory Board, Premier Medical Corporation, 2015, Gujarat
  19. Chairperson, IMAPAC 5th Annual Vaccine World India Summit, Pune, March 2015
  20. International Travel Award/Fellowship: International AIDS Vaccine Conference, Cape Town, South Africa, 2008.
  21. Visiting Scholar, Duke University, Durham, North Carolina, USA (July-August, 2007)
  22. Research Fellowship Grant Award from The American Foundation for AIDS Research (amfAR), USA, 2004-2006.
  23. UNESCO-ASM Visiting Resource Person Program Award, 2005.
  24. Travel Grant Award 11th Conference on Retrovirus & Opportunistic infection, San Francisco, CA, USA 2004.
  25. Travel Grant Award 12th Conference on Retrovirus & Opportunistic infection, Boston, MA, USA, 2005
  26. Prof. P.B. Sen Memorial award from The Physiological Society of India (1998).
  27. Senior and Junior Research Fellowships from Indian Council of Medical Research (1993-1998).
  28. Prof Arun Sen Award for ranking FIRST in B.Sc. (Honors), Burdwan University, 1989.

Member of Professional Bodies

  1. Member, National Academy of Sciences, Allahabad, India
  2. Past Member, Task Force (Infectious Disease Biology Study Section), Department of Biotechnology, Govt of India
  3. Member, Scientific Advisory Board, Premier Medical Corporation Ltd., Nani Daman, Gujarat.
  4. Member, American Society of Microbiology
  5. Life member, Physiological Society of India

Editorial Board Member

  1. Academic Editor and Member of the Editorial Board, PLoS One.
  2. Associate Editor & Senior Editorial Management Team, Therapeutic Advances in Vaccines, SAGE Publications Ltd, London, UK
  3. Member, Editorial Board of World Journal of Virology, Baishideng Publishing Group.
  4. Section Editor & Senior Editorial Board Member, VirusDisease, Springer Publications Inc.













IAVI Investigators:

1. Dr Ranajoy Mullick, Senior Scientist IAVI

2. Dr Sohini Mukherjee, Senior Specialist, IAVI

3. Dr Jyoti Sutar, Senior Research Associate/Specialist, IAVI

  • 01292876307